Practical guidelines for the use of long-acting injectable second-generation antipsychotics

被引:13
|
作者
Jarema, Marek [1 ]
Wichniak, Adam [1 ]
Dudek, Dominika [2 ]
Samochowiec, Jerzy [3 ]
Bienkowski, Przemyslaw [4 ]
Rybakowski, Janusz [5 ]
机构
[1] III Psychiat Clin, Inst Psychiat & Neurol Warsaw, PL-02957 Warsaw, Poland
[2] Jagiellonian Univ, Coll Med, Chair Psychiat, Dept Affect Disorders, PL-31007 Krakow, Poland
[3] Pomeranian Med Univ, Dept Psychiat, Szczecin, Poland
[4] Inst Psychiat & Neurol, Dept Pharmacol, Warsaw, Poland
[5] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland
关键词
schizophrenia; long-acting antipsychotics; arpiprazole; olanzapine; paliperidone; risperidone; guidelines for use; DOUBLE-BLIND; SCHIZOPHRENIA; ARIPIPRAZOLE; DRUGS; HOSPITALIZATION; FORMULATIONS; OUTCOMES; DEPOT;
D O I
10.12740/PP/39370
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.
引用
收藏
页码:225 / 241
页数:17
相关论文
共 50 条
  • [21] EVIDENCE FOR THE USE OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS
    Amladi, Anjani
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S44 - S44
  • [22] The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
    Miyamoto S.
    Wolfgang Fleischhacker W.
    Current Treatment Options in Psychiatry, 2017, 4 (2) : 117 - 126
  • [23] Long-acting injectable antipsychotics: second-generation compared to first-generation drugs. Clinical outcomes and reflections
    Parise, V. Fricchione
    Addeo, L.
    Laezza, R.
    Balletta, G.
    Manna, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S535 - S536
  • [24] Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics A Retrospective Chart Review and Prescribers' Attitude Survey
    Misawa, Fuminari
    Amemiya, Ami
    Fujii, Yasuo
    Takeuchi, Hiroyoshi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2022, 42 (01) : 81 - 86
  • [25] Long-acting injectable second-generation antipsychotics: conditions of reimbursement after repeated hospitalization and estimated the budgetary impact
    Minarcikova, Ivana
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (06) : 1753 - 1753
  • [26] Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
    Prikryl, Radovan
    Kucerova, Hana Prikrylova
    Vrzalova, Michaela
    Ceskova, Eva
    SCHIZOPHRENIA RESEARCH AND TREATMENT, 2012, 2012
  • [27] Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate
    Joshi, Kruti
    Pan, Xiaoyun
    Wang, Rosa
    Yang, Erru
    Benson, Carmela
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1873 - 1881
  • [28] Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
    Llorca, Pierre Michel
    Abbar, Mocrane
    Courtet, Philippe
    Guillaume, Sebastien
    Lancrenon, Sylvie
    Samalin, Ludovic
    BMC PSYCHIATRY, 2013, 13
  • [29] Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
    Pierre Michel Llorca
    Mocrane Abbar
    Philippe Courtet
    Sebastien Guillaume
    Sylvie Lancrenon
    Ludovic Samalin
    BMC Psychiatry, 13
  • [30] Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia
    Pesa, Jacqueline
    Liu, Zhiwen
    Fu, Alex Z.
    Campbell, Alicia K.
    Grucza, Richard
    SCHIZOPHRENIA RESEARCH, 2023, 261 : 170 - 177